The Impact of Anticholinergic Burden on the Development of Mild Behavioral Impairment
- PMID: 42242938
- DOI: 10.1016/j.jagp.2026.05.008
The Impact of Anticholinergic Burden on the Development of Mild Behavioral Impairment
Abstract
Objective: Mild behavioral impairment (MBI) is a syndrome of late-life-onset persistent neuropsychiatric symptoms. Anticholinergic medication is commonly prescribed in older adults. Both MBI and anticholinergic exposure are associated with increased dementia risk. We sought to understand the association of anticholinergic burden (ACB) with MBI.
Design, setting, participants: We mapped ratings on the Neuropsychiatric Inventory Questionnaire to the MBI checklist (MBI-C) using an established algorithm to define MBI status in cognitively unimpaired individuals in the National Alzheimer's Coordinating Center database. We then assessed the association between time-varying ACB ratings and risk of incident MBI.
Results: 4865 participants met inclusion criteria and were followed for a mean (SD) of 5.64 (3.92) years. ACB scores ranged from 0 to 11. 63.3% of participants had a score of 0, 27.7% had a score of 1-2, and 9% had a score of ≥3. Higher maximum total ACB score was associated with a higher likelihood of developing MBI (p ≤0.001). When assessed as a time varying covariate, ACB score was associated with incident MBI (HR 1.07, 95% CI 1.02-1.14, p = 0.010). This association remained significant when adjusted for 10-year mortality risk, age, sex, education, and race.
Conclusions: MBI risk should be considered when prescribing anticholinergic medication in older adults.
Keywords: Mild behavioral impairment; anticholinergic medication; dementia; neuropsychiatric symptoms; older adults.
Copyright © 2026 The Authors. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
DISCLOSURES PBR has received honoraria from Lilly, GLG, Leerink, Acadia, Medalink, Novo Nordisk, Noble Insights, TwoLabs, Otsuka, Lundbeck, Acadia, MedaCorp, ExpertConnect, HMP Global, Sinaptica, Worldwide Clinical Trials, Medscape, and Neurology Week. CGL has served as paid consultant or advisor for Astra-Zeneca, Glaxo-Smith Kline, Eisai, Novartis, Forest, Supernus, Adlyfe, Takeda, Wyeth, Lundbeck, Merz, Lilly, Pfizer, Genentech, Elan, NFL Players Association, NFL Benefits Office, Zinfandel, BMS, Abvie, Janssen, Orion, Servier, Astellas, SVB Leerink, Roche, Avanir, Karuna, Maplight, Axsome, GIA, GW Research Limited, Merck, EXCIVA GmbH, Otsuka, IntraCellular Therapies, Medesis, BMS, Abbvie. ZI has served as advisor/consultant for the Canadian Agency for Drugs and Technology in Health, Eisai, Lilly, Lundbeck/Otsuka, Novo Nordisk, and Roche. CEF and JML have no conflicts of interest to declare.
Update of
-
The impact of anticholinergic burden on the development of mild behavioral impairment.medRxiv [Preprint]. 2025 Dec 7:2025.12.05.25341723. doi: 10.64898/2025.12.05.25341723. medRxiv. 2025. Update in: Am J Geriatr Psychiatry. 2026 Aug;34(8):1019-1030. doi: 10.1016/j.jagp.2026.05.008. PMID: 41409670 Free PMC article. Updated. Preprint.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous